We purchased p85α, Akt1,
p-IKKα/β (Ser180/Ser181), p-IκBα, p65 (Ser536
), IKKα/β, IκBα, p65, CCN6, and
β-actin primary antibodies (Santa Cruz Biotechnology, CA, USA), and
rabbit polyclonal antibodies specific for p-p85 (Y458), p-Akt (S473), p-mTOR (Ser2448), and mTOR (Cell Signaling Technology, Danvers, MA, USA). Recombinant human CCN6 was purchased from PerpoTech (Rocky Hill, NJ, USA) and CCN6 short hairpin (sh)RNA expression plasmids from RNAiCore (Taipei, Taiwan). The
D-Luciferin potassium salt was purchased from Gold Biotechnology (St. Louis, MO, USA).
Lipofectamine 2000 and
TRIzol were purchased from Life Technologies (Carlsbad, CA, USA). Dharmacon Research (Lafayette, CO, USA) supplied ON-TARGETplus siRNAs. Gibco-BRL life technologies (Grand Island, NY, USA) supplied
DMEM,
α-MEM,
fetal bovine serum (FBS), and all other cell culture reagents. The Matrigel was purchased from BD (Biosciences, Bedford, MA, USA) and Promega (Madison, WI,) supplied the
pSV-β-Galactosidase Vector and
luciferase assay kits. All other USA chemicals or inhibitors that we used were supplied by Sigma-Aldrich (St. Louis, MO, USA).
Tzeng H.E., Tang C.H., Wu S.H., Chen H.T., Fong Y.C., Lu Y.C., Chen W.C., Huang H.D., Lin C.Y, & Wang S.W. (2018). CCN6-mediated MMP-9 activation enhances metastatic potential of human chondrosarcoma. Cell Death & Disease, 9(10), 955.